N. Anthony Coles
Chairperson and Chief Executive Officer
TONY COLES is chairperson and chief executive officer of Cerevel Therapeutics, a biopharmaceutical company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. He first joined Cerevel as chairperson in December 2018 and become the chief executive officer in September 2019. Dr. Coles is also a founding investor and the chairperson of the board of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases. Prior to co-founding Yumanity Therapeutics, Dr. Coles served as the chairperson and chief executive officer of TRATE Enterprises, LLC. Previously, Dr. Coles served as president, chief executive officer and chairperson of the board of Onyx Pharmaceuticals, Inc. Prior to joining Onyx Pharmaceuticals, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Dr. Coles also previously served as a member of the Harvard Medical School Board of Fellows. Dr. Coles currently serves on the board of directors of Regeneron Pharmaceuticals, Inc., is a member of the Board of Trustees for Johns Hopkins University, and serves as an advisor for General Atlantic. He is also Vice Chair of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the Board of Trustees of The Metropolitan Museum of Art in New York; a member of the Aspen Economic Strategy Group, a program of the Aspen Institute; and a member of the Board of Directors of the Council on Foreign Relations. In 2021, Dr. Coles was elected to the American Academy of Arts & Sciences. Dr. Coles earned his bachelor’s degree at Johns Hopkins University, his medical degree from Duke University, and his master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.